Shares of biotechnology firm Humacyte, Inc. (HUMA) skyrocketed by a staggering 52.87% in Friday's pre-market trading session. This massive surge came after the company announced late on Thursday that the U.S. Food and Drug Administration (FDA) has granted full approval for its bioengineered human tissue product SYMVESS (acellular tissue engineered vessel-tyod).
The FDA approval allows SYMVESS to be used in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when an autologous vein graft is not feasible. This marks a significant milestone for Humacyte and the field of regenerative medicine.
SYMVESS is a first-of-its-kind, off-the-shelf implantable bioengineered human tissue that can serve as a vascular conduit for arterial replacement and repair. In clinical testing, SYMVESS demonstrated high rates of blood flow patency and low rates of complications such as amputation and infection when used for treating various traumatic arterial injuries like gunshot wounds, car accidents, and blast injuries.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。